BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23062104)

  • 1. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
    Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
    Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
    Go RS
    Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
    [No Abstract]   [Full Text] [Related]  

  • 3. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2-V617F and BCR-ABL--double jeopardy?
    Krämer A
    Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
    [No Abstract]   [Full Text] [Related]  

  • 5. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance.
    Martin-Cabrera P; Haferlach C; Kern W; Schnittger S; Haferlach T
    Br J Haematol; 2017 Jan; 176(1):135-139. PubMed ID: 26847954
    [No Abstract]   [Full Text] [Related]  

  • 6. A Patient With BCR-ABL and JAK2 V617F Double-Positive Myeloproliferative Neoplasm With Overlapping Clinical Phenotypes.
    Wang Y; Xia J; Wu X; Hu Y
    Am J Med Sci; 2015 Jul; 350(1):68-9. PubMed ID: 25798831
    [No Abstract]   [Full Text] [Related]  

  • 7. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH
    Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between JAK2-V617F mutations and variation of peripheral blood cells among BCR/ABL-negative MPD patients].
    Ye YX; Song XB; Zhou Y; Ying BW; Lu XJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Oct; 29(5):582-6. PubMed ID: 23042399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
    Siddiqui NS; Ssiddiqui HS; Qurat-Ul-Ain ; Siddiqui SA
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):423. PubMed ID: 20642980
    [No Abstract]   [Full Text] [Related]  

  • 11. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
    Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
    Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant presence of JAK2V617F mutation and BCR‑ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report).
    Mousinho F; Azevedo AP; Mendes T; Santos PSE; Cerqueira R; Matos S; Santos S; Ramos S; Viana JF; Lima F
    Mol Med Rep; 2018 Jul; 18(1):1001-1006. PubMed ID: 29845291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
    Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
    Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.
    Bornhäuser M; Mohr B; Oelschlaegel U; Bornhäuser P; Jacki S; Ehninger G; Thiede C
    Leukemia; 2007 Aug; 21(8):1824-6. PubMed ID: 17476275
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
    Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
    Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
    [No Abstract]   [Full Text] [Related]  

  • 17. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
    Bader G; Dreiling B
    J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
    Koopmans SM; Schouten HC; van Marion AM
    Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of JAK2 mutations in myeloproliferative disorders.
    Knoops L; Hermans C; Ferrant A; Constantinescu SN
    Acta Clin Belg; 2008; 63(2):93-8. PubMed ID: 18575049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.